CAR-37 T cells(The General Hospital)

N/A

Report date: 2025/03/14 20:00:48

Base Information

Drug NameCAR-37 T cells(The General Hospital)
Drug Alias Nameanti-CD37 CAR T-cell therapy (Massachusetts General Hospital)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLeukocyte antigen CD37 modulators
TargetsLeukocyte antigen CD37
Therapy Area/IndicationsHematologic NeoplasmsLymphoma, T-CellLymphoma, B-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe General Hospital Corporation D/B/A Massachusetts General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesThe General Hospital Corporation D/B/A Massachusetts General Hospital
Inactive CompaniesN/A
Active IndicationsHematologic NeoplasmsLymphoma, T-CellLymphoma, B-Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A